MX2012006484A - 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina. - Google Patents

3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina.

Info

Publication number
MX2012006484A
MX2012006484A MX2012006484A MX2012006484A MX2012006484A MX 2012006484 A MX2012006484 A MX 2012006484A MX 2012006484 A MX2012006484 A MX 2012006484A MX 2012006484 A MX2012006484 A MX 2012006484A MX 2012006484 A MX2012006484 A MX 2012006484A
Authority
MX
Mexico
Prior art keywords
sub
compounds
nicotinic acetylcholine
neuronal nicotinic
heptanes
Prior art date
Application number
MX2012006484A
Other languages
English (en)
Inventor
Balwinder Singh Bhatti
Srinivasa Rao Akireddy
Ronald Joseph Heemstra
Srinivasa V Murthy
Jon-Paul Strachan
Yunde Xiao
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012006484(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of MX2012006484A publication Critical patent/MX2012006484A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con compuestos que se unen y modulan la actividad de receptores nicotínicos neuronales de acetilcolina, con procesos para preparar estos compuestos, con composiciones farmacéuticas que contienen estos compuestos, y con métodos para usar estos compuestos para tratar una amplia variedad de condiciones y trastornos, que incluyen aquellos asociados a la disfunción del sistema nervioso central (SNC).
MX2012006484A 2009-12-07 2010-12-03 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina. MX2012006484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26721809P 2009-12-07 2009-12-07
PCT/US2010/058836 WO2011071758A1 (en) 2009-12-07 2010-12-03 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
MX2012006484A true MX2012006484A (es) 2012-08-01

Family

ID=43608875

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006484A MX2012006484A (es) 2009-12-07 2010-12-03 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina.

Country Status (21)

Country Link
US (2) US8802694B2 (es)
EP (1) EP2509982A1 (es)
JP (1) JP2013512922A (es)
KR (1) KR20120120190A (es)
CN (1) CN102648202A (es)
AR (1) AR079271A1 (es)
AU (1) AU2010328419A1 (es)
BR (1) BR112012013765A2 (es)
CA (1) CA2782409A1 (es)
CL (1) CL2012001483A1 (es)
CO (1) CO6541649A2 (es)
EC (1) ECSP12012023A (es)
IL (1) IL219960A0 (es)
MX (1) MX2012006484A (es)
PE (1) PE20121556A1 (es)
PH (1) PH12012501068A1 (es)
RU (1) RU2012128583A (es)
SG (1) SG181109A1 (es)
TW (1) TW201138776A (es)
WO (1) WO2011071758A1 (es)
ZA (1) ZA201204143B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1976828T3 (pl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Pochodne diaminy jako inhibitory hydrolazy leukotrienu a4
MX2012006484A (es) * 2009-12-07 2012-08-01 Targacept Inc 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina.
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
CN102875556B (zh) * 2011-07-12 2016-03-30 天津药明康德新药开发有限公司 (4s)-1-取代-2,5-二氮杂双环[2,2,1]庚烷衍生物及制备方法
TW201311698A (zh) * 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素を阻害する方法
AU2014239585B2 (en) 2013-03-14 2019-04-04 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
EP2968264A4 (en) 2013-03-14 2016-11-02 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
AU2014239567B2 (en) 2013-03-14 2017-12-14 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
CA3102077A1 (en) 2018-05-31 2019-12-05 Sanjeev AHUJA Method of reducing pulmonary exacerbations in respiratory disease patients

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
JP4570773B2 (ja) 1997-10-27 2010-10-27 ニューロサーチ、アクティーゼルスカブ ニコチン性アセチルコリンレセプターに於けるコリン作動性リガンドとしてのヘテロアリールジアザシクロアルカン
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
DE60008866T2 (de) * 1999-05-04 2005-01-27 Neurosearch A/S Heteroaryl diazabicycloalkene, deren herstellung und verwendung
EP1185514A1 (en) 1999-06-07 2002-03-13 Targacept, Inc. Pharmaceutical compositions and methods for use
EP1212319A2 (en) 1999-09-14 2002-06-12 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
AU780492B2 (en) 1999-11-01 2005-03-24 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6624167B1 (en) 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
AU2002322562A1 (en) 2001-07-19 2003-03-03 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
MXPA04010966A (es) * 2002-05-07 2005-01-25 Neurosearch As Derivados novedosos de biarilo diazabiciclico.
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
BRPI0417323A (pt) * 2003-12-22 2007-03-27 Memory Pharm Corp indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos
ITMI20040954A1 (it) * 2004-05-12 2004-08-12 Univ Degli Studi Milano Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US20110071180A1 (en) * 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
MX2012006484A (es) * 2009-12-07 2012-08-01 Targacept Inc 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina.

Also Published As

Publication number Publication date
SG181109A1 (en) 2012-07-30
TW201138776A (en) 2011-11-16
CO6541649A2 (es) 2012-10-16
CL2012001483A1 (es) 2013-01-18
WO2011071758A1 (en) 2011-06-16
EP2509982A1 (en) 2012-10-17
ECSP12012023A (es) 2012-08-31
CA2782409A1 (en) 2011-06-16
AR079271A1 (es) 2012-01-04
KR20120120190A (ko) 2012-11-01
CN102648202A (zh) 2012-08-22
US20120309737A1 (en) 2012-12-06
JP2013512922A (ja) 2013-04-18
BR112012013765A2 (pt) 2016-04-26
PH12012501068A1 (en) 2013-02-04
US20140315880A1 (en) 2014-10-23
RU2012128583A (ru) 2014-01-20
PE20121556A1 (es) 2012-12-05
ZA201204143B (en) 2013-02-27
US8802694B2 (en) 2014-08-12
AU2010328419A1 (en) 2012-06-21
IL219960A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
MX2012006484A (es) 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina.
SG179453A1 (en) Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
MX2010005110A (es) Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
UA98098C2 (ru) ПРОИЗВОДНЫЕ ПИРИДИНОНА И ИХ ПРИМЕНЕНИЕ КАК ПОЛОЖИТЕЛЬНЫХ АЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
ATE503754T1 (de) 1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit
WO2010096384A3 (en) Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
UA98317C2 (ru) СОЕДИНЕНИЯ С АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ НИКОТИНОВОГО АЦЕТИЛХИНОЛИНОВОГО РЕЦЕПТОРА α7 (α7-NACHR), КОМПОЗИЦИЯ, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
MX2010002537A (es) 4-fenil-1h-piridin-2-onas 1,3-disubstituidas.
MY152078A (en) 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
EA017914B8 (ru) 1,4-ДВУЗАМЕЩЕННЫЕ 3-ЦИАНОПИРИДОНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЗИТИВНЫХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
MY152387A (en) Preparation and therapeutic applications of (2s,3r)-n-2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-3,5-difluorobenzamide
MX2011003691A (es) Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
NO20070347L (no) Modulatorer av alfa7 nikotinske acetylkolinreseptorer og terapeutiske anvendelser
MX2010002538A (es) 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas.
MY155212A (en) Quaternary ammonium salt compounds
PH12014500775A1 (en) Ethynyl derivatives as mglur5 allosteric modulators
MX2010009727A (es) Amidas selectivas del subtipo del receptor nicotinico de acetilcolina de diazabicicloalcanos.
IL202236A0 (en) Prolinamide derivatives as nk3 antagonists
MX2015006062A (es) Compuestos de pirazolo [3,4-d] pirimidina sustituidos, su preparacion y su uso como ligandos de sigma.
MY159040A (en) Compounds
MX2012004317A (es) Com puestos de azabiciclo[2.2.1] heptano como ligandos de receptor de acetilcolina alfa-7-nicotinico.
MX340508B (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
WO2010017093A3 (en) Dopamine receptor ligands with enhanced duration of action
PH12014500413A1 (en) 1,4-diazabicyclo[3.2.2]nonanes as neuronal nicotinic acetylcholine receptor ligands
MX2010002585A (es) Derivados de piperidina como antagonistas del receptor nk3.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal